Aeterna Zentaris Inc. (NASDAQ:AEZS) has risen 15.47% to $1.08 in premarket trading hours on the last check Monday. At the close of Friday’s trading session, Aeterna stock had increased by 0.43% to reach $0.94. In terms of price, AEZS stock ranged between $0.92 and $0.96.
There were 1.77 million shares traded, which is below its daily average of 14.04 million over the past 100 days. The AEZS stock has increased in absence of recent news, so recent developments may provide a better idea of the AEZS’s future direction.
In addition to commercializing and developing therapeutics and diagnostic tests, Aeterna Zentaris also provides diagnostic services. An oral test based on macimorelin has been approved for the diagnosis of adult growth hormone deficiency (AGHD) by the U.S. Food and Drug Administration (FDA) and by the European Commission. The drug is currently sold under the trade name Macrilen in the United States under a license agreement with Novo Nordisk, where AEZS receives royalties based on net sales.
Aeterna Zentaris GmbH is the wholly-owned subsidiary of Aeterna Zentaris and is a biopharmaceutical company specializing in the development and commercialization of therapeutic and diagnostic tests. Aeterna recently announced it had exercised a February 2, 2021 option and has entered into an exclusive worldwide sub-license agreement on patents and know-how.
The agreement was reached for the potential development of a vaccine against COVID-19 that has been invented at the Julius-Maximilians-University Wuerzburg, one of Germany’s most renowned research and teaching institutions. Furthermore, Aeterna entered into a research agreement with the University to facilitate supplementary research activities and clinical trials on this potential vaccine.
What AEZS is eyeing on?
Aeterna Zentaris (AEZS) plans to test a swath of candidate vaccines in vitro and in vivo and select the one that is most active and stable for preclinical testing or further clinical development. In order to develop an oral dosage form of COVID-19 vaccine that is also effective against mutated viruses and can be stored in a common fridge and manufactured with relatively low costs of goods, AEZS’ goal is to produce the vaccine in an oral dose form.